On April 6, Jingfeng Pharmaceutical issued an announcement stating that recently, its subsidiary Guizhou Jingfeng Injection Co.
has obtained the "Drug Supplementary Application for Tirofiban Hydrochloride Sodium Chloride Injection" approved and issued by the State Food and Drug Administration.
Approval Notice", this product has passed the generic drug quality and efficacy consistency evaluation
Tirofiban Hydrochloride Sodium Chloride Injection is mainly used for adult patients with non-ST-segment elevation acute coronary syndrome (NSTE-ACS) who have ECG changes and/or elevated myocardial enzymes within 12 hours of the last chest pain onset , To prevent early myocardial infarction.
The patients most likely to benefit are those who have a higher risk of myocardial infarction within the first 3-4 days after the onset of acute angina symptoms, including those who may undergo early percutaneous coronary intervention (PCI).
It is used for patients with acute myocardial infarction (STEMI) who are planning to undergo direct PCI to reduce the occurrence of major cardiovascular events.
This product should be used together with unfractionated heparin and aspirin.
Tirofiban is a platelet glycoprotein IIb/IIIa receptor antagonist.
It has the advantages of rapid onset of action, definite efficacy, and rapid recovery of platelet function after stopping the drug.
It has been listed in the European "Guidelines for Myocardial Revascularization (2018)" , China's "Acute ST-segment elevation myocardial infarction diagnosis and treatment guidelines (2019)", China's "Acute ST-segment elevation myocardial infarction rational use guidelines for thrombolytic therapy (2019)" and other domestic and foreign authoritative guidelines recommended for use.
Tirofiban Hydrochloride Sodium Chloride Injection is a category B product of the National Medical Insurance in 2020, and its sales in China in 2019 are about 190 million yuan.